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Background: Antiretrovirals (ARVs) are the molecules used in the fight 
against infection by the Human Immunodeficiency Virus (HIV). Their main 
objective is to stop the virus from replicating and thus allow the immune sys-
tem to recover. In 2001, the program to fight against HIV/AIDS United Na-
tions (UNAIDS) and its partners has decided to strengthen the pharmaceuti-
cal channel and improve access to good quality care. Thus ARV quality con-
trol is recommended. Objective: The objective of this work was to monitor 
the quality of ARVs distributed in Kinshasa. Methodology: In this work, 
UV-visible spectrophotometry is used for the analysis of ARVs presented in 
simple form distributed in the city of Kinshasa. Results: The results of this 
work show that the stated and analyzed ARVs contain active ingredients; 
there is no placebo. Ten percent of these ARVs are non-compliant with regard 
to dosing of the active test. Conclusion: These results confirm the need to 
control these drugs to protect patients from adverse consequences related to 
their poor quality. 
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1. Introduction 
Antiretrovirals (ARVs) are molecules used to fight against the Human Immu-
nodeficiency Virus (HIV) infection [1]. The main objective of these molecules is 
to slow down the virus replication and thus allow the immune system to recover, 
to make the plasmatic Viral Load (VL) undetectable (<50 RNA/ml copies) which 
allows better immune restoration and reduces the risk of selection of resistant 
virus [1]. 
In 2001, the United Nations program to fight against HIV/AIDS (UNAIDS) 
and its partners has addressed the problems of drug quality in their generic form 
[2]. This program is more interested in ARV in resource limited countries where 
generics are often of dubious quality and quantitatively under dosage recom-
mendation [2] [3]. UNAIDS has decided to strengthen the pharmaceutical 
channel of these countries and improve access to quality care for all patients be-
cause poverty and disorganization of the pharmaceutical sector are the main 
reasons for the phenomenon of counterfeiting [4]. The qualitative and quantita-
tive analysis of ARV is therefore recommended. This must be done regularly, 
internally and externally, and be reported to the appropriate authorities [1]. It 
should be performed throughout the pharmaceutical supply circuit; from manu-
facture to use. At reception and storage point, each batch of ARVs must be sub-
ject to quality control [1]. 
The National Programs against HIV/AIDS (PNMLS and PNLS) are the main 
national bodies in the fight against the epidemic and the care of People Living 
with HIV (PLHIV) in the country. Their main strategies are focused on educa-
tion and outreach; free voluntary testing in different centers, management, the-
rapeutic monitoring and psychosocial assistance for eligible patients [5]. 
In the Democratic Republic of Congo (DRC), the most commonly used mo-
lecules, as of 2012, are: Abacavir (ABC), Efavirenz (EFV), Lamivudine (3TC), 
Lopinavir boosted by Ritonavir (LPV/r), Nevirapine (NVP), Stavudine (d4T) 
and Zidovudine (ZDV) [5]. All these molecules are pre-qualified generic by the 
World Health Organization (WHO); however, pre-qualification does not ex-
clude quality control in the provision for use by the patient [2]. 
This study aimed to control the quality of some ARVs distributed in Kinshasa 
[6]. The targeted molecules in this study were: Abacavir (ABC), Efavirenz (EFV), 
Nevirapine (NVP) and Zidovudine (ZDV). 
2. Materials and Methods 
2.1. Framework 
This study was conducted in the period from the August 20, 2013 to January, 20 
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2014. Quality control analyses were performed at Laboratory of Molecular Biol-
ogy of the Faculty of Medicine of the University of Kinshasa (UNIKIN), 
LAPHAKI and AVEPHARMA Laboratories, all in Kinshasa. 
2.2. Analyzed Molecules 
The molecules analyzed in this study are presented in Table 1. They were freely 
donated by different monitoring centers for HIV patients in Kinshasa [5]. 
2.3. Selection of Samples 
The sample selection was made randomly in the received packages. Twenty pills 
of each drug were used for the analysis. 
2.4. Materials 
The UV-Visible spectrophotometer (HP/Agilent 8453) with Agilent Technolo-
gies ChemStation software (Gyeonggi-do, South Korea) was used for the study. 
The wavelengths used were 285 nm for Abacavir (ABC) [7] and Nevirapine 
(NVP) [7] [8], 266 nm for Zidovudine (ZDV) [7] [9] and 254 nm for Efavirenz 
(EFV) [7]. Friabilimeter was of Erweka brand and tablet disintegration was 
achieved with a device of the Labfine model Dit-200 brand from Research Lab 
Fine Chem (Mumbai, India). 
 
Table 1. List of Antiretrovirals used in this study. 
NOM DU MEDICAMENT  
(SPECIALITE) D C I Manufacturer 
Batch  
Number 
Origin of  
Manufacturer 
Abacavir sulfate 
Pills of 300 mg Abacavir 
Matrix labo 
Limited 1082374 India 
Abacavir sulfate 
Pills of 300 mg Abacavir 
Aurobindo 
 AB3011030A India 
Abacavir sulfate 






Pills of 300 mg Zidovudine Ranbaxy 2359701 India 
EstivaN® 
Pills of 600 mg Efavirenz 
Hétéro labs 
Iimited E120314A India 
Nevipan® 
Pills of 200 mg Nevirapine Ranbaxy 2386326 India 
Nevimune® 
Pills of 200 mg Nevirapine Cipla X10889 India 
Nevirapine 






Pills of 200 mg Nevirapine Strides NE2012089-A India 
Nevirapine 
Pills of 200 mg Nevirapine Aurobindo NE2012089-A India 




The substances of references used were obtained from Sigma Aldrich of Belgium 
(Efavirenz-98.1% and Zidovudine-98.0%), USP Millipore (Nevirapine-99.7%) 
and Cayman Chemical Lansing of the United States of America (Abaca-
vir-100%). Methanol and methylene chloride used for these analyzes were pro-
vided by Merck of Germany. The ultrapure water was produced using the Aqua 
Max-Basic™ 360 series device of YL Instruments of South Korea. 
2.6. Pharmaco-Technical Tests 
Performed according to the recommendations of the European Pharmacopoeia 
8.1 [10], the friability test was performed by weighing a given number of pills 
equivalent to 6.5g. This assay allows estimating the strength of the tablets during 
the packaging operations, and possible coating and transport. The pills disinte-
gration was completed in ultrapure water placed at 37˚C for 15 minutes to de-
termine the ability to disintegrate in a prescribed time in liquid medium. 
2.7. Methods 
The friability assays, the chemo-physical assays and the spectrophotometric as-
says used in this study are all described in the literature [6]-[14]. The standards 
assay being set from 90.0% to 110.0%. 
2.8. Preparation of Standard Solutions 
Standard solutions of 1 mg/ml were prepared from the reference chemicals of 
different molecules each dissolved in 100 ml of solvent (methanol for EFV, NVP 
and ZDV; ultrapure water for ABC). Different concentrations (5 μg/ml, 10 µg/ml 
and 15 μg/ml) were used to draw the calibration line in the type of y = ax + b (a: 
as the slope of the equation; b: as origin coordinate; x: as the concentration; y: as 
the analytical response or absorbance). The coefficient of determination (R2) was 
used as a quality indicator for the calibration slope. After the linearity of the ca-
libration slope was confirmed, it was used to calculate the sample concentra-
tions.  
3. Results and Discussion 
The samples used in this study were provided without charge by different cen-
ters of treatment and supported for People Living with HIV/AIDS in Kinshasa. 
Table 1 provides information on the various molecules used; he presents the 
name of the drug, the International Nonproprietary Name (INN), the manufac-
turer's name, the batch number and the manufacturer's country of origin. All 
these molecules are manufactured by Indian pharmaceutical companies (Matrix 
Lab Limited, Aurobindo Pharma Limited, Ranbaxy, Hetero Labs Limited, Cipla 
and Strides Arcolab Limited). 
Table 2 shows the results of tests friability obtained for the 10 analyzed spe-
cialties. All molecules were analyzed in accordance with a loss of weight less than 
1% by. These tablets can therefore hold up well during packaging and transpor-




Table 3 presents the results of the disintegration test of the 10 molecules 
tested. This Physicochemical test provides information on the potential release 
of active ingredient from the oral dosage form in a required time and good dis-
integration of such tablets in the gastrointestinal tract because the disintegration 
promotes bioavailability of drug [6] [10]. These molecules were compliant in re-
lation to disaggregation time; they all have a time inferior than 15 minutes. 
Further then, the molecules were identified through their Ultra Violet (UV) 
spectra through the methods used. These UV spectra are shown in Figure 1 for 
all 4 analyzed molecules. In all samples tested, there was concordance between 
the standard UV spectrum and that found in the sample, allowing confirming 
the identity of the different molecules analyzed. They all contain the active prin-
ciple as declared by the manufacturer. 
After determination of UV spectra, the molecules were quantified using the 
calibration lines. The results of the quantification of the molecules are shown in  
 
Table 2. Results of the friability assays with the studied drugs. 






Abacavir sulfate 0.6 
Abacavir sulfate 0.8 
Abacavir sulfate 0.9 
Estiva - 600® 0.5 
Aviroz® 0.5 
 
Table 3. Results of disintegration assays with the studied drugs. 
Specialties Observed time in minute 
Abacavir sulfate 4 
Abacavir sulfate 10 
Abacavir sulfate 10 
Aviroz® 13 
Estivan® 12 









Figure 1. UV-Spectrum obtained for the studied molecules.  
 
Table 4. In all cases, R2 is close to 1. These different molecules show good ad-
justment to the calibration line obtained meaning that there is a correlation be-
tween the introduced concentration and the analytical response represented by 
the absorbance. The calibration lines are validated, they were then used to de- 
termine concentrations such as Y bx
a
−
=  and content of active substances in  
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Table 4. Dosage results of studied drugs. 
Specialties Equation of  the lines R² 
% ± standard  
deviation Decision 
Abacavir sulfate Y= 0.038X + 0.153 0.998 105% ± 0.12% Conformed 
Abacavir sulfate Y= 0.038X + 0.196 0.998 105% ± 0.67% Conformed 
Abacavir sulfate Y= 0.039X + 0.001 0.999 101% ± 0.78% Conformed 
Aviroz ® Y= 0.028X + 0.0241 0.994 107% ± 0.45% Conformed 
Estiva 600® Y= 0.039X + 0.0001 0.999 101% ± 0.56% Conformed 
Nevipan® Y= 0.034X + 0.010 0.998 99% ± 0.89% Conformed 
Nevimune® Y= 0.28X + 0.20 0.998 94% ± 0.78% Conformed 
Nevirapine Y= 0.014X + 0.219 0.986 115% ± 0.90% Non Conformed 
Nevirapine Y= 0.032X + 0.001 0.995 103.6% ± 0.56% Conformed 
Nevirapine Y= 0.028X + 0.020 0.990 97.5% ± 0.87% Conformed 
 
the samples [14]. A molecule analyzed out of ten (Nevirapine of Strides Arcolab 
Limited) is non-compliant in relation to the dosage of the active ingredient. This 
molecule is overdosed (115%) which is a poisoning threat to patients. 
These results are similar to those described in our environment [6], ARVs 
distributed in Kinshasa are of good quality, but there is still 1 set that captures 
the attention. Hence the need to widely implement quality control of ARVs. 
4. Conclusion and Perspective 
The objective of this study was to monitor the quality of antiretroviral medicines 
presented in non-combined form distributed in Kinshasa using UV-Visible 
spectrophotometry. The molecules used for this study are: Abacavir, Efavirenz, 
Nevirapine and Zidovudine. 
The results obtained from the 10 analyzed molecules show that all these 
products contain the active ingredients stated and satisfy to friability testing and 
disintegration of tablets. However, a molecule (10%) is non-compliant in accor-
dance with dosing tests, which poses a risk of toxicity for the patient. This de-
monstrates the need for quality control of ARVs prior to distribution in Kinsha-
sa. 
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